Key result
mRNA COVID-19 vaccines are linked to steroid-responsive eosinophilic myocarditis driven by cationic protein release.
Why the study?
Severe myocarditis may occur after COVID-19 mRNA (BNT162b2) vaccination, but its pathway, morphomolecular characterization, and treatment remain unknown.
Does prednisone improve cardiac contractility in patients with hypersensitivity eosinophilic myocarditis following COVID-19 mRNA vaccination?
Case Report (n=3)
Does prednisone improve cardiac contractility in patients with hypersensitivity eosinophilic myocarditis following COVID-19 mRNA vaccination?
Severe myocarditis following COVID-19 mRNA vaccination can be mediated by an eosinophilic hypersensitivity reaction that responds well to a short course of corticosteroids.
Answers are grounded in this paper and cite their sources.
May warrant vigilance for eosinophilic myocarditis post-mRNA vaccination; hypothesis-generating and requires prospective confirmation.
BACKGROUND: Myocarditis, even in a severe and lethal form, may occur after COVID-19 mRNA (BNT162b2) vaccination. However, its pathway, morphomolecular characterization and treatment are still unknown. METHODS: Routine hematochemical screening, ECG, Holter monitoring, 2D echocardiogram cardiac magnetic resonance (CMR) and invasive cardiac studies (cardiac catheterization, selective coronary angiography, left ventriculography and left ventricular endomyocardial biopsy) are reported from three patients (39F-pt1, 78M-pt2, 52M-pt3) with severe compromise of conduction tissue (junctional rhythm and syncope, pt1) or cardiac function compromise (LVEF ≤ 35%, pt2 and pt3) after COVID-19 mRNA (BNT162b2). RESULTS: Hematochemical data and coronary angiography were normal in the patients studied. Histology showed in all three patients extensive myocardial infiltration of degranulated eosinophils and elevation of serum cationic protein directly responsible for cardiomyocyte damage. These findings demonstrate myocarditis hypersensitivity to some component of the vaccine (spike protein?) acting as a hapten to some macromolecules of cardiomyocytes. Steroid administration (prednisone, 1 mg/kg die for 3 days, followed by 0.33 mg/kg for 4 weeks) was followed by complete recovery of cardiac contractility in pt2 and pt3. CONCLUSIONS: Eosinophilic myocarditis is a possible adverse reaction to the mRNA COVID-19 vaccine. Its pathway is mediated by release of cationic protein and responds to short courses of steroid administration.
No takes yet. Share an insight, caveat, or question.
Frustaci et al. (2022) conducted a case report in Hypersensitivity Myocarditis after COVID-19 mRNA Vaccination (n=3). COVID-19 mRNA (BNT162b2) vaccination was evaluated on Histological findings and response to steroid administration. Eosinophilic myocarditis is a possible adverse reaction to the mRNA COVID-19 vaccine, mediated by cationic protein release, and responds to short courses of steroid administration.
Synapse has enriched 10 related papers. Consider them for comparative context: